

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM433788

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Barclays Bank PLC		06/28/2017	Public Limited Company: ENGLAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Dendreon Pharmaceuticals LLC		
<b>Street Address:</b>	1208 Eastlake Avenue East		
<b>City:</b>	Seattle		
<b>State/Country:</b>	WASHINGTON		
<b>Postal Code:</b>	98102		
<b>Entity Type:</b>	Limited Liability Company: WASHINGTON		
<b>PROPERTY NUMBERS Total: 12</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3228929	ANTIGEN DELIVERY CASSETTE	
<b>Registration Number:</b>	2188041	DACS	
<b>Registration Number:</b>	2465920	DENDREON	
<b>Registration Number:</b>	2530065	DENDREON	
<b>Registration Number:</b>	3616391	DENDREON	
<b>Registration Number:</b>	4099276	DENDREON	
<b>Registration Number:</b>	3581626	DENDREON	
<b>Registration Number:</b>	4158044		
<b>Registration Number:</b>	3581625		
<b>Registration Number:</b>	3726707	DENDREON TARGETING CANCER, TRANSFORMING	
<b>Registration Number:</b>	3982430	DENDREON TARGETING CANCER, TRANSFORMING	
<b>Registration Number:</b>	2545242	PROVENGE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2023704750		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Darlena Bari Stark		

OP \$315.00 3228929

**Address Line 1:** 1025 Vermont Ave NW, Suite 1130  
**Address Line 2:** COGENCY GLOBAL INC.  
**Address Line 4:** Washington, D.C. 20005

<b>ATTORNEY DOCKET NUMBER:</b>	F171135 TM Rel
<b>NAME OF SUBMITTER:</b>	Emily Ohannessian
<b>SIGNATURE:</b>	/EMILY OHANNESSIAN/
<b>DATE SIGNED:</b>	07/05/2017

**Total Attachments: 6**

source=#89843664v1 - (Executed Trademark Release Agreement)#page2.tif  
source=#89843664v1 - (Executed Trademark Release Agreement)#page3.tif  
source=#89843664v1 - (Executed Trademark Release Agreement)#page4.tif  
source=#89843664v1 - (Executed Trademark Release Agreement)#page5.tif  
source=#89843664v1 - (Executed Trademark Release Agreement)#page6.tif  
source=#89843664v1 - (Executed Trademark Release Agreement)#page7.tif

**RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS**

This RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS (this “Release”) is entered into as of June 28, 2017 by Barclays Bank PLC, a public limited company with offices located at 745 Seventh Avenue, New York, New York 10019, as Collateral Agent for the Secured Parties (in its capacity as successor agent to Goldman Sachs Lending Partners LLC (“Goldman”)) (the “Assignor”), in favor of Dendreon Pharmaceuticals LLC, a Delaware limited liability company (formerly known as Dendreon Pharmaceuticals, Inc., a Delaware corporation) with offices located at 1208 Eastlake Avenue East, Seattle, WA 98102, (the “Assignee”). Capitalized terms used in this Release but not defined herein shall have the respective meanings ascribed to such terms in the Pledge and Security Agreement or Trademark Security Agreement (each as defined below), as applicable.

**WHEREAS**, reference is made to (i) that certain Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012, as amended by Amendment No. 1, dated as of March 6, 2012, by Amendment No. 2, dated as of September 10, 2012, by Amendment No. 3, dated as of January 24, 2013, by Amendment No. 4, dated as of February 21, 2013, by Amendment No. 5, dated as of June 6, 2013, by Amendment No. 6, dated as of June 26, 2013, by Amendment No. 7, dated as of September 17, 2013, by Amendment No. 8, dated as of December 20, 2013 by the Successor Agent Agreement, Amendment No. 9, dated as of January 8, 2015, Amendment No. 10, dated as of March 5, 2015, Amendment No. 11, dated as of May 29, 2015, by Amendment No. 12 and Waiver, dated as of April 11, 2016, by Amendment No. 13, dated as of August 23, 2016, by Amendment No. 14 dated as of March 21, 2017, by Amendment No. 15, dated as of March 28, 2017, and as further supplemented by the Joinder Agreements, dated as of June 14, 2012, July 9, 2012, September 11, 2012, October 2, 2012, December 11, 2012, each of the Joinder Agreements dated as of August 5, 2013, and each of the Joinder Agreements dated as of February 6, 2014, by the Joinder Agreements, each dated as of January 22, 2015 and by the Joinder Agreements, each dated as of April 1, 2015 (as it may be amended, restated, replaced, supplemented or otherwise modified from time to time, the “Credit Agreement”) among Valeant Pharmaceuticals International, Inc., a corporation continued under the laws of the Province of British Columbia (“VPII”), certain subsidiaries of VPII, as guarantors, the lenders from time to time party thereto, the Assignor and the others party thereto; (ii) that certain Pledge and Security Agreement, dated as of June 29, 2011, as amended by the Amended and Restated Pledge and Security Agreement, dated as of October 20, 2011, and as further amended by the Second Amended and Restated Pledge and Security Agreement, dated as of February 13, 2012 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Pledge and Security Agreement”), between the Assignee and the other grantors party thereto and the Assignor; and (iii) that certain Trademark Security Agreement, dated as of June 29, 2011 between the Assignor (as collateral agent) and the Assignee and other grantors party thereto (the “Trademark Security Agreement”);

**WHEREAS**, pursuant to the terms and conditions of the Trademark Security Agreement, the Assignee granted to the Assignor, for the benefit of the Secured Parties, a security interest in and continuing lien on all of the Assignee’s right, title and interest in, to and under the following, in each case whether then owned or thereafter acquired by the Assignee or in which the Assignee

then had or thereafter acquired any right, title or interest and wherever the same may be located (collectively, the "Trademark Collateral"):

all United States and foreign trademarks, trade names, trade dress, corporate names, company names, business names, fictitious business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers, designs and general intangibles of a like nature, whether or not registered, and with respect to any and all of the foregoing: (i) all registrations and applications therefor including, without limitation, the registrations and applications listed in Schedule A attached to the Trademark Security Agreement, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit then or thereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world;

**WHEREAS**, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on July 27, 2015 at Reel 5585, Frame 0445;

**WHEREAS**, pursuant to that certain Officer's Certificate dated as of June 28, 2017 (the "Certificate"), VP II certified to the Assignor that the Assignee sold the trademarks set forth on Schedule I hereto (the "Specified Trademark"), which sale has been consummated by the Assignee and the purchaser as of June 28, 2017, as provided in the Certificate; and

**WHEREAS**, the Assignor, solely in reliance on the representations, warranties and certifications made pursuant to the Certificate and without independent investigation, has agreed to terminate and release its security interest solely in the Specified Trademark and Specified Trademark Collateral (as defined below) related thereto.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor, on behalf of itself, its successors, legal representatives and assigns and any lenders for which the Assignor acted as security or collateral agent, hereby unconditionally terminates, releases, discharges and reassigns to the Assignee fully, without representation, warranty or recourse, its security interest in and continuing lien on all of the Assignee's right, title and interest in, to and under (i) the Specified Trademark, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds or the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit then or thereafter due and/or payable with respect thereto (but excluding, for the avoidance of doubt, Proceeds from the sale by the Assignee of the Specified Trademark as referenced in the Certificate), and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world (collectively, the "Specified Trademark Collateral").

The Assignor hereby authorizes the Assignee or the Assignee's authorized representative to record this Release with the United States Patent and Trademark Office ("USPTO") and any other offices as may be necessary to carry out the intention of this Release, and to the extent applicable, the Assignor authorizes and requests that the USPTO record this Release.

The Assignor shall execute and deliver any and all documents or other instruments reasonably requested by the Assignee, and at the Assignee's sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

This Release and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.

Delivery of an executed signature page to this Release by facsimile or electronic transmission (including .pdf file) shall be effective as delivery of an original signature.

For the avoidance of any doubt, this Release is strictly limited solely and only to the Specified Trademark Collateral and to no other Trademark Collateral. The Assignor continues to maintain, without interruption or impairment, its security interest in all of the Assignee's right, title and interest in, to and under all Trademark Collateral other than the Specified Trademark Collateral. The provisions of the Trademark Security Agreement and the Pledge and Security Agreement shall, except as modified by this Release, continue in full force and effect.

**THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES  
HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND  
ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK  
WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.**

[Remainder of page intentionally left blank]

**IN WITNESS WHEREOF**, the Assignor has caused this Release to be executed and delivered by its duly authorized officer as of the date first set forth above.

BARCLAYS BANK PLC,  
as Collateral Agent

By: \_\_\_\_\_

Name:

Title: **Christopher M. Aitkin**  
Assistant Vice President

Signature Page to Release of Security Interest in Specified Trademarks

**TRADEMARK**  
**REEL: 006098 FRAME: 0442**

**SCHEDULE I**  
to  
**RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS**

Specified Trademark

<b>No.</b>	<b>Jurisdiction</b>	<b>Registered Owner</b>	<b>Mark</b>	<b>App. No.</b>	<b>Reg. No.</b>	<b>App. Date</b>	<b>Reg. Date</b>
1.	United States	DENDREON PHARMACEUTICALS, INC.	ANTIGEN DELIVERY CASSETTE	78651515	3228929	6/15/2005	4/10/2007
2.	United States	DENDREON PHARMACEUTICALS, INC.	DACS	74681428	2188041	5/30/1995	9/8/1998
3.	United States	DENDREON PHARMACEUTICALS, INC.	DENDREON	75283623	2465920	4/29/1997	7/3/2001
4.	United States	DENDREON PHARMACEUTICALS, INC.	DENDREON	75282526	2530065	4/29/1997	1/15/2002
5.	United States	DENDREON PHARMACEUTICALS, INC.	DENDREON (REFILED)	76165904	3616391	11/9/2000	5/5/2009
6.	United States	DENDREON PHARMACEUTICALS, INC.	DENDREON AND DESIGN	77463413	4099276	5/1/2008	2/14/2012
7.	United States	DENDREON PHARMACEUTICALS, INC.	DENDREON AND DESIGN	78395105	3581626	4/1/2004	2/24/2009
8.	United States	DENDREON PHARMACEUTICALS, INC.	DENDREON MISCELLANEOUS DESIGN	77463424	4158044	5/1/2008	6/12/2012
9.	United States	DENDREON PHARMACEUTICALS, INC.	DENDREON MISCELLANEOUS DESIGN	78395102	3581625	4/1/2004	2/24/2009
10.	United States	DENDREON PHARMACEUTICALS, INC.	DENDREON TARGETING CANCER, TRANSFORMING LIVES (STYLIZED WITH DESIGN)	78733522	3726707	10/14/2005	12/15/2009
11.	United States	DENDREON PHARMACEUTICALS, INC.	DENDREON TARGETING CANCER, TRANSFORMING LIVES AND DESIGN (STYLIZED WITH DESIGN)	78733533	3982430	10/14/2005	6/21/2011
12.	United States	DENDREON PHARMACEUTICALS, INC.	PROVENGE	75927064	2545242	2/23/2000	3/5/2002

13.	Australia	DENDREON CORPORATION	DENDREON	920752	920752	7/24/2002	3/4/2003
14.	Canada	DENDREON CORPORATION	DENDREON	1148456	TMA799137	7/30/2002	6/2/2011
15.	Canada	DENDREON CORPORATION	DENDREON TARGETING CANCER, TRANSFORMING LIVES AND DESIGN (STYLIZED WITH DESIGN)	1685568		7/16/2014	
16.	Canada	DENDREON CORPORATION	PROVENGE	1537312	TMA848037	7/27/2011	4/3/2013
17.	China	DENDREON CORPORATION	DENDREON	3338807	3338807	10/17/2002	5/7/2004
18.	China	DENDREON CORPORATION	DENDREON	3462760	3462760	2/20/2003	9/21/2004
19.	European Union	DENDREON CORPORATION	DENDREON	2786317	2786317	7/24/2002	1/21/2004
20.	European Union	DENDREON CORPORATION	DENDREON AND DESIGN	3919081	3919081	7/12/2004	11/16/2005
21.	European Union	DENDREON CORPORATION	PROVENGE	1816974	1816974	8/21/2000	10/5/2001
22.	European Union	DENDREON CORPORATION	Design Only	3919073	3919073	7/12/2004	11/16/2005
23.	Hong Kong	DENDREON CORPORATION	DENDREON	200211420	200316300	7/24/2002	12/30/2003
24.	Ireland	DENDREON CORPORATION	DENDREON	2002/01488	225773	7/25/2002	7/25/2002
25.	Japan	DENDREON CORPORATION	DENDREON	2002-071245	4748818	8/22/2002	2/20/2004
26.	Japan	DENDREON CORPORATION	DENDREON AND DESIGN	2004-082921	4844098	9/8/2004	3/4/2005
27.	Japan	DENDREON CORPORATION	DENDREON AND DESIGN	2004-082922	4854919	9/8/2004	4/8/2005
28.	Japan	DENDREON CORPORATION	DENDREON AND DESIGN	2004-065404	4844005	7/14/2004	3/4/2005
29.	Japan	DENDREON CORPORATION	PROVENGE	2002-046880	4655127	6/6/2002	3/20/2003
30.	Japan	DENDREON CORPORATION	Design Only	2004-065401	4825474	7/14/2004	12/10/2004
31.	Japan	DENDREON CORPORATION	Design Only	2004-065402	4844004	7/14/2004	3/4/2005
32.	New Zealand	DENDREON CORPORATION	DENDREON	661517	661517	7/29/2002	3/3/2003
33.	New Zealand	DENDREON CORPORATION	DENDREON	664161	664161	9/9/2002	3/13/2003
34.	Norway	DENDREON CORPORATION	DENDREON	200206940	218776	7/26/2002	5/2/2003
35.	Republic of Korea	DENDREON CORPORATION	DENDREON	4020020034025	4005753300000	7/25/2002	2/23/2004
36.	Switzerland	DENDREON CORPORATION	DENDREON	06607/2002	507918	7/26/2002	3/4/2003

**TRADEMARK**

**RECORDED: 07/05/2017**

**REEL: 006098 FRAME: 0444**